[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP0618927A4 - Cytokines with an unpaired cysteine residue and conjugates thereof. - Google Patents

Cytokines with an unpaired cysteine residue and conjugates thereof.

Info

Publication number
EP0618927A4
EP0618927A4 EP93901259A EP93901259A EP0618927A4 EP 0618927 A4 EP0618927 A4 EP 0618927A4 EP 93901259 A EP93901259 A EP 93901259A EP 93901259 A EP93901259 A EP 93901259A EP 0618927 A4 EP0618927 A4 EP 0618927A4
Authority
EP
European Patent Office
Prior art keywords
conjugates
cytokines
cysteine residue
unpaired cysteine
unpaired
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93901259A
Other languages
German (de)
French (fr)
Other versions
EP0618927A1 (en
Inventor
Tse Wen Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of EP0618927A1 publication Critical patent/EP0618927A1/en
Publication of EP0618927A4 publication Critical patent/EP0618927A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP93901259A 1991-12-10 1992-12-10 Cytokines with an unpaired cysteine residue and conjugates thereof. Withdrawn EP0618927A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80545291A 1991-12-10 1991-12-10
US805452 1991-12-10
PCT/US1992/010889 WO1993012142A1 (en) 1991-12-10 1992-12-10 Cytokines with an unpaired cysteine residue and conjugates thereof

Publications (2)

Publication Number Publication Date
EP0618927A1 EP0618927A1 (en) 1994-10-12
EP0618927A4 true EP0618927A4 (en) 1995-05-24

Family

ID=25191607

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93901259A Withdrawn EP0618927A4 (en) 1991-12-10 1992-12-10 Cytokines with an unpaired cysteine residue and conjugates thereof.

Country Status (5)

Country Link
EP (1) EP0618927A4 (en)
JP (1) JP2704214B2 (en)
AU (1) AU666914B2 (en)
CA (1) CA2124672A1 (en)
WO (1) WO1993012142A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165458A (en) * 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
JP2003500053A (en) * 1999-05-20 2003-01-07 サイオス,インコーポレーテッド Vascular endothelial growth factor dimer
AU5023300A (en) 1999-05-20 2000-12-12 Scios Inc. Vascular endothelial growth factor variants
DE10144252A1 (en) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanoparticles with biologically active TNF immobilized on them
GB0123262D0 (en) * 2001-09-27 2001-11-21 Adprotech Ltd Polymeric compounds

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105777A1 (en) * 1982-09-22 1984-04-18 Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) Lipopeptides, their manufacture and use as emulsifiers
EP0236987A2 (en) * 1986-03-10 1987-09-16 F. Hoffmann-La Roche Ag Chemically modified protein and production thereof
EP0354992A2 (en) * 1988-07-08 1990-02-21 Yeda Research And Development Company Limited Conjugates of VIP and active fragments thereof with hydrophobic moieties and topical compositions for use in the treatment of male impotence
WO1990012874A2 (en) * 1989-04-21 1990-11-01 Genetics Institute, Inc. Cysteine added variants of polypeptides and chemical modifications thereof
EP0441765A1 (en) * 1990-02-09 1991-08-14 Washington University Novel fatty acid analog enzyme substrates
WO1991012229A1 (en) * 1990-02-12 1991-08-22 National Research Council Of Canada Process for preparing acyl derivatives of acylatable compounds
EP0458064A2 (en) * 1990-05-04 1991-11-27 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105777A1 (en) * 1982-09-22 1984-04-18 Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) Lipopeptides, their manufacture and use as emulsifiers
EP0236987A2 (en) * 1986-03-10 1987-09-16 F. Hoffmann-La Roche Ag Chemically modified protein and production thereof
EP0354992A2 (en) * 1988-07-08 1990-02-21 Yeda Research And Development Company Limited Conjugates of VIP and active fragments thereof with hydrophobic moieties and topical compositions for use in the treatment of male impotence
WO1990012874A2 (en) * 1989-04-21 1990-11-01 Genetics Institute, Inc. Cysteine added variants of polypeptides and chemical modifications thereof
EP0441765A1 (en) * 1990-02-09 1991-08-14 Washington University Novel fatty acid analog enzyme substrates
WO1991012229A1 (en) * 1990-02-12 1991-08-22 National Research Council Of Canada Process for preparing acyl derivatives of acylatable compounds
EP0458064A2 (en) * 1990-05-04 1991-11-27 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO9312142A1 *
WILCOX ET AL: "THE MAJORITY OF CELLULAR FATTY ACID ACYLATED PROTEINS ARE LOCALIZED TO THE CYTOPLASMIC SURFACE OF THE PLASMA MEMBRANE", BIOCHEMISTRY, vol. 26, 1987, WASHINGTON D.C.,USA, pages 1029 - 1036 *

Also Published As

Publication number Publication date
WO1993012142A1 (en) 1993-06-24
AU3323593A (en) 1993-07-19
CA2124672A1 (en) 1993-06-24
JPH07502508A (en) 1995-03-16
AU666914B2 (en) 1996-02-29
EP0618927A1 (en) 1994-10-12
JP2704214B2 (en) 1998-01-26

Similar Documents

Publication Publication Date Title
GB2252794B (en) Co-rotational scroll apparatus with improved scroll member biasing
HU9301988D0 (en) N-alkyl-quinuclidine-salts with p-material-antagonist effect
ZA929335B (en) Device.
ZA919797B (en) Bicyclo-5,6-dihydro-7h-pyrrolo-1,20-imidazol-7-ols and 7-ones
ZA928908B (en) An absorbent article.
EP0604504A4 (en) Iontotherapeutic device and process.
GB2239218B (en) Luminescent drawing or sketching device.
GB9121641D0 (en) Sampler
GB9023214D0 (en) Electronic parts and electronic device incorporating the same
ZA923592B (en) Glass composition and use.
ZA929294B (en) Syringe.
GB9104713D0 (en) An improved micro-endoscope
GB9021047D0 (en) Electronic parts and electronic device incorporating the same
EP0618927A4 (en) Cytokines with an unpaired cysteine residue and conjugates thereof.
KR0113532Y1 (en) Drawaway tip
HU9201804D0 (en) Gingerole and gingerdiole derivatives for decreasing cholesterole, with anti-arterosclerosys effect
EP0522547A3 (en) Carbonyl-containing degradable chelants, uses and compositions thereof
GB2256619B (en) Mechanical pencil with lead-feeding device
EP0653254A3 (en) Press with press table and mobile table.
ZA926056B (en) Penile support arrangement and member.
AU112710S (en) Pen
EP0591518A4 (en) Amplified mixer-blower mechanism and uses thereof.
EP0523005A3 (en) Disazodyes with cycloalkylester or cycloalkylamide rests
GB9124767D0 (en) Envelope with opener
EP0537970A3 (en) Output circuit with buffer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940708

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19950406

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19981116

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990327